Nephrology

52.5% reduction with high-dose and 47.7% reduction with low-dose combination compared to baseline, and an acceptable tolerability profile. Novel investigational drug leverages SGLT2 inhibition and high selectivity ETA receptor antagonism with potential to deliver step-change efficacy and acceptable fluid retention.

843.6 million people worldwide are living with chronic kidney disease (CKD), a progressive and potentially fatal condition. Yet, the majority remain undiagnosed and untreated.

Chronic kidney disease (CKD) is a serious, progressive condition and under-recognised public health problem, affecting nearly 840 million people worldwide. More than 9 million people living with CKD have progressed to kidney failure, requiring dialysis or a kidney transplant, and by 2040, CKD is expected to become the world’s 5th leading cause of mortality.